Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement for Severe Aortic Stenosis in Patients With Chronic Kidney Disease Stages 3b to 5 Paola D’Errigo, MS, Claudio Moretti, MD, Fabrizio D’Ascenzo, MD, Stefano Rosato, MS, Fausto Biancari, MD, Marco Barbanti, MD, Francesco Santini, MD, Marco Ranucci, MD, Antonio Miceli, MD, Corrado Tamburino, MD, Francesco Onorati, MD, Gennaro Santoro, MD, Claudio Grossi, MD, Danilo Fusco, MS, Fulvia Seccareccia, MS The Annals of Thoracic Surgery Volume 102, Issue 2, Pages 540-547 (August 2016) DOI: 10.1016/j.athoracsur.2016.01.109 Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Cox-adjusted analysis of the impact of baseline chronic kidney disease (CKD) stages on the intermediate all-cause mortality in patients undergoing transcatheter or surgical aortic valve replacement for severe aortic stenosis. The Annals of Thoracic Surgery 2016 102, 540-547DOI: (10.1016/j.athoracsur.2016.01.109) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Intermediate survival and freedom from major adverse cardiac and cerebrovascular events (MACCE) in propensity score–matched pairs of patients with chronic kidney disease (CKD) stages 3b to 5 after transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) for severe aortic stenosis. The Annals of Thoracic Surgery 2016 102, 540-547DOI: (10.1016/j.athoracsur.2016.01.109) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions